Terug
43
26
Dagbereik
€ 71,00
€ 71,00
52-Weeksbereik
€ 47,50
€ 74,00
Volume
100
50D / 200D Gem.
€ 67,99
/
€ 62,85
Vorige Slotkoers
€ 71,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 21,7 | 0,4 |
| P/B | 6,8 | 2,9 |
| ROE % | 38,5 | 3,8 |
| Net Margin % | 17,3 | 3,9 |
| Rev Growth 5Y % | 11,9 | 10,0 |
| D/E | 0,8 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
-€ 0,37
-€ 0,41 – -€ 0,32
|
220 M | 1 |
| FY2028 |
€ 0,89
€ 0,78 – € 0,97
|
200 M | 1 |
| FY2027 |
€ 4,67
€ 4,05 – € 5,09
|
260 M | 1 |
Belangrijkste Punten
Revenue grew 11,93% annually over 5 years — strong growth
Earnings declined -48,17% over the past year
ROE of 38,49% indicates high profitability
Net margin of 17,30% shows strong profitability
Generating 59,50M in free cash flow
Cash machine — converts 147,94% of earnings into free cash flow
Groei
Revenue Growth (5Y)
11,93%
Revenue (1Y)11,49%
Earnings (1Y)-48,17%
FCF Growth (3Y)112,22%
Kwaliteit
Return on Equity
38,49%
ROIC16,91%
Net Margin17,30%
Op. Margin22,20%
Veiligheid
Debt / Equity
0,79
Current Ratio5,11
Interest Coverage0,00
Waardering
P/E Ratio
21,66
P/B Ratio6,81
EV/EBITDA18,26
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11,49% | Revenue Growth (3Y) | 21,45% |
| Earnings Growth (1Y) | -48,17% | Earnings Growth (3Y) | 96,17% |
| Revenue Growth (5Y) | 11,93% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 232,51M | Net Income (TTM) | 40,22M |
| ROE | 38,49% | ROA | 14,26% |
| Gross Margin | 83,09% | Operating Margin | 22,20% |
| Net Margin | 17,30% | Free Cash Flow (TTM) | 59,50M |
| ROIC | 16,91% | FCF Growth (3Y) | 112,22% |
| Safety | |||
| Debt / Equity | 0,79 | Current Ratio | 5,11 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 21,66 | P/B Ratio | 6,81 |
| P/S Ratio | 3,75 | PEG Ratio | -0,31 |
| EV/EBITDA | 18,26 | Dividend Yield | 0,00% |
| Market Cap | 871,33M | Enterprise Value | 942,65M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 232,51M | 208,54M | 157,63M | 147,77M | 148,12M |
| Net Income | 40,22M | 77,59M | 10,45M | 12,15M | -6,83M |
| EPS (Diluted) | 3,14 | 5,83 | 0,86 | 1,02 | -0,58 |
| Gross Profit | 193,19M | 169,86M | 130,84M | 123,16M | 124,05M |
| Operating Income | 51,62M | 61,18M | 19,21M | 18,54M | 1,19M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 282,13M | 257,76M | 173,29M | 220,85M | 247,27M |
| Total Liabilities | 154,13M | 176,77M | 183,29M | 265,86M | 305,87M |
| Shareholders' Equity | 128,00M | 81,00M | -10,00M | -45,01M | -58,61M |
| Total Debt | 100,98M | 111,67M | 128,61M | 187,14M | 218,96M |
| Cash & Equivalents | 29,66M | 120,70M | 59,90M | 84,70M | 53,70M |
| Current Assets | 251,85M | 220,91M | 152,15M | 175,36M | 241,07M |
| Current Liabilities | 49,24M | 45,56M | 47,59M | 74,85M | 174,41M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#553 of 1024
Custom
Capital Light Compounder
#173 of 213
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Capital Light Compounder
Mar 24, 2026